What segments are in the U.S. Orthopedic Biomaterials market?
The U.S. orthopedic biomaterials market includes bone graft substitutes, growth factors, cellular allografts, cell therapies, hyaluronic acid viscosupplementation, and cartilage repair.
Bone graft substitutes fill bone voids or act as extenders to eliminate the need for autograft harvesting.
Growth factors are naturally occurring proteins within the human body, and the growth factor products exploit their regenerative properties in bone repair surgeries.
Cellular allografts consist of allograft bone combined with stem cells. These offer a complete solution for bone repair through osteoconduction, osteoinduction, and osteogenesis.
Cell therapies are cell concentration systems that take a portion of blood or bone marrow and produce a concentrate.
Hyaluronic acid viscosupplementation is a product used for direct injection into the knee to relieve pain caused by osteoarthritis.
Finally, cartilage repair products utilize cartilage in multiple different ways to treat patients.
What does the future have in store for this market?
Over the forecast period, the U.S. orthopedic biomaterials market expects to reach about $5 billion by 2025 with a CAGR of 6%. Among the six segments included in the overall market, the largest was hyaluronic acid viscosupplementation. Alone, this market had a valuation of over $1.1 billion, constituting one-third of the market.
Hyaluronic acid viscosupplementation products will be a driver of the market’s projected growth over the forecast period. The most rapidly growing segment, on the other hand, is the cellular allograft market. This market previously had a valuation of nearly $350 million and expects to double by 2025. The cellular allograft market growth is due to stem cell’s increasing popularity and excellent candidacy for bone repair.
COVID-19 Impact On Orthopedic Procedures
COVID-19 significantly delayed the number of procedures performed. In 2020, the total traumatic orthopedic injury rates and scheduled orthopedic procedures reduced significantly. The reduction in treatments was because the orthopedic procedures for hip and knee replacements are mainly within the high-risk, above-50 demographic. However, as more Americans get vaccinated and restrictions lift, the market will return to previous trajectories by 2022. Macroeconomic recoveries will also strongly impact the spending potential in this market towards more expensive, new technologies.
What companies are competing within the U.S. orthopedic biomaterials market?
Medtronic, DePuy Synthes, and Zimmer Biomet are the top three leaders within the orthopedic biomaterials market. The company that led the market with nearly a 20% share and the largest share in the bone graft substitutes segment was Medtronic. Medtronic also has its dominating product, INFUSE™, present within the growth factor market.
DePuy Synthes similarly had traction within the bone graft substitute market as well as the cellular allograft segments. The company sells its DMB product line that is processed by the Musculoskeletal Transplant Foundation (MTF).
Lastly, Zimmer Biomet has a strong presence in the bone graft substitute, cellular allograft, cell therapy, hyaluronic acid, and cartilage repair segments. Zimmer Biomet’s product portfolio includes their DBM RegenerOss™, FiberStack™, and StaGraft™ DBM Putty and Plus products.
The overall U.S. biomaterials market has six segments including hyaluronic acid viscosupplementation which is the largest market and the cellular allograft market which is the fastest-growing. By 2025, this market expects to reach a valuation of over $3.5 billion. Medtronic, DePuy Synthes, and Zimmer Biomet are the leading competitors within the market. All three of these companies have a dominant stance within the bone graft substitute segment and multiple products available within the other segments. COVID-19 significantly delayed the number of procedures performed due to the high average age of patients receiving hip and knee replacements. Despite this, the market is indicating strong signs of recovery into 2022.